266 related articles for article (PubMed ID: 30828569)
1. Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.
Werner JM; Schweinsberg V; Schroeter M; von Reutern B; Malter MP; Schlaak M; Fink GR; Mauch C; Galldiks N
Front Oncol; 2019; 9():84. PubMed ID: 30828569
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
4. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
5. Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade.
Sun MM; Seleme N; Chen JJ; Zekeridou A; Sechi E; Walsh RD; Beebe JD; Sabbagh O; Mejico LJ; Gratton S; Skidd PM; Bellows DA; Falardeau J; Fraser CL; Cappelen-Smith C; Haines SR; Hassanzadeh B; Seay MD; Subramanian PS; Williams Z; Gordon LK
J Neuroophthalmol; 2021 Dec; 41(4):519-530. PubMed ID: 33136674
[TBL] [Abstract][Full Text] [Related]
6. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Makarious D; Horwood K; Coward JIG
Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
[TBL] [Abstract][Full Text] [Related]
7. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
8. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.
Fazel M; Jedlowski PM
Case Reports Immunol; 2019; 2019():2539493. PubMed ID: 31183226
[TBL] [Abstract][Full Text] [Related]
9. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
10. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
[TBL] [Abstract][Full Text] [Related]
11. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
12. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.
Meerveld-Eggink A; Rozeman EA; Lalezari F; van Thienen JV; Haanen JBAG; Blank CU
Ann Oncol; 2017 Apr; 28(4):862-867. PubMed ID: 28158487
[TBL] [Abstract][Full Text] [Related]
13. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
Lau KH; Kumar A; Yang IH; Nowak RJ
Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
15. A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary.
Gaballa S; Hlaing KM; Mahler N; Moursy S; Ahmed A
Cureus; 2020 Jun; 12(6):e8602. PubMed ID: 32676241
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
Koppolu V; Rekha Vasigala VK
J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
Carreau NA; Pavlick AC
Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of immune checkpoint inhibitors.
Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
[TBL] [Abstract][Full Text] [Related]
19. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]